Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study

Next Previous
Trial Profile

Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs N-acetylcysteine-amide (Primary)
  • Indications Cerebral amyloid angiopathy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AT1-HCCAA
  • Sponsors Arctic Therapeutics

Most Recent Events

  • 11 Apr 2025 New source identified and integrated ( EudraCT2017-004776-56 ).
  • 02 Apr 2025 According to an Arctic Therapeutics media release, results were published in JAMA Neurology.
  • 02 Apr 2025 Results presented in the Arctic Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top